Shire extends Fosrenol program to cover Part D enrollees

March 5, 2007

Shire is launching a new Medicare Part D component under the Fosrenol At Hand program. Through this program addition, Shire will now provide Fosrenol (lanthanum carbonate)—a therapy used to treat hyperphosphatemia (high phosphorus levels in the blood)—free to qualifying patients who are enrolled in a Medicare prescription drug plan. Through the Fosrenol At Hand program, Shire provides help to patients who have no coverage for Fosrenol under prescription drug benefits, Medicare, Medicaid, or other state-funded programs. With the addition of the new Medicare Part D assistance component, qualifying patients enrolled in a Part D plan but who can't afford their co-pays or co-insurance along with those facing the Medicare Part D doughnut hole may now receive Fosrenol free of charge. Patients will receive monthly quantities of the drug through the end of the calendar year in which they enroll in the program. Fosrenol is indicated to reduce serum phosphate in patients with end-stage renal disease. For more information, call 1-(866) 325-8223.

Shire is launching a new Medicare Part D component under the Fosrenol At Hand program. Through this program addition, Shire will now provide Fosrenol (lanthanum carbonate)—a therapy used to treat hyperphosphatemia (high phosphorus levels in the blood)—free to qualifying patients who are enrolled in a Medicare prescription drug plan. Through the Fosrenol At Hand program, Shire provides help to patients who have no coverage for Fosrenol under prescription drug benefits, Medicare, Medicaid, or other state-funded programs. With the addition of the new Medicare Part D assistance component, qualifying patients enrolled in a Part D plan but who can't afford their co-pays or co-insurance along with those facing the Medicare Part D doughnut hole may now receive Fosrenol free of charge. Patients will receive monthly quantities of the drug through the end of the calendar year in which they enroll in the program. Fosrenol is indicated to reduce serum phosphate in patients with end-stage renal disease. For more information, call 1-(866) 325-8223.

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.